



Julie Lovelady, Medicaid Director

Hawki Clinical Advisory Committee (CAC)

AGENDA
Hawki CAC
Thursday, April 15, 2021
Time: 7:30 – 8:30 a.m.
Conference Call

Dial: 1-866-685-1580
Code: 000 999 0230

Meeting Objective

To engage clinicians to provide the best care and services for the pediatric population covered by the Hawki Program.

Roll Call	Diane Morrill
Opening	Dr. Jagiello
Approval of Minutes	Dr. Jagiello
Introduction of Else Umbreit, PharmD	Dr. Jagiello
High-Cost Physician Administered Medications (PAM)	Dr. Jagiello
COVID-19 Update	Dr. Jagiello
Open Discussion	Dr. Jagiello
Closing	Dr. Jagiello

Next meetings:

July 15, 2021
October 21, 2021
January 20, 2022
April 21, 2022



Hawki Clinical Advisory Committee
Minutes of Meeting January 21, 2021

CAC Members Present:

Teri Wahlig, MD
Stephanie Sinclair, NP
William Howard, MD
Deb Bixler, DO

Hawki and contract staff present:

Bill Jagiello, DO, Hawki CAC Chair
Diane Morrill, IME
Dr. Paul Mulhausen, ITC
Dr. Leslie Schechtman, AGP
Gretchen Hageman, Delta Dental

CAC Members Absent:

Stacy Wagner, MD

Roll call of CAC members and MCOs. Meeting was opened at 7:35 a.m.

The minutes from the October 2020 meeting were approved as written. There were no Hawki Board updates.

A general discussion was initiated regarding COVID-19 vaccines. The Infectious Disease Advisory Council (IDAC) has been holding weekly meetings to discuss vaccination priorities. Changes are anticipated due to new administration. The IDAC timeline was shared with the CAC members following the meeting. Phases 1A and 1B have rolled out. Several front-line CAC members added that ChildServe will be vaccinating their members with disabilities.

Dr. Jagiello shared IME Informational Letter No. 2207 regarding COVID-19 Vaccines and Monoclonal Antibodies with the meeting attendees. The purpose of the IL is to inform and update providers regarding the release of COVID-19 vaccines and Monoclonal Antibodies to treat COVID-19. This IL also included information regarding billing and coding for administration fees.

An email from Paula Motsinger, Bureau Chief, Bureau of Medical and LTSS Policy was discussed. Paula is reaching out to providers and wanting input regarding telehealth services that should be continued post-pandemic. This email was forwarded to all CAC members following the meeting. The QIO is reviewing telehealth services that have been utilized using claims data. Most notably, behavioral health telehealth services have been utilized during the pandemic and continuation of those services will be recommended to IME and DHS leadership. Other areas where services will be recommended would include members in LTC/SNF facilities with conferences between member, care team, and providers which would likely reduce the number of ER visits as

their primary care provider is not available for consultation. Telehealth services for primary care are being reviewed as well.

A discussion was initiated regarding off-label drug use for ADHD medications. FDA approved indications for ADHD medications begin at 6 years of age. The American Association of Pediatricians supports off-label use of these medications for children 3 to 6 years of age. Although stimulants are not the first line of approach in treating children younger than 6 years of age, these medications need to be available for these children when alternative treatments have not been successful. IME is currently working on a policy that would support off-label use based on published literature and research. There have been exception to policy requests received and approved when medically necessary for some off-label uses.

Areas where difficulties have been noted in the past include point of sale pharmacy benefits that deny drugs that should be available. The QIO has hired a staff pharmacist that will be attending DUR and P&T meetings in the future to bring these issues to those forums. It is expected that this interaction will help to align drugs that are medical necessary with POS pharmacy benefits. She will provide insight to pharmacy benefits and help providers navigate the system. The new pharmacist will join the next scheduled Hawki CAC meeting. CAC members were urged to have examples of such issues available for this discussion.

The next scheduled meeting will be April 15, 2021, with subsequent meetings on July 15, and October 21, 2021 (third Thursday quarterly).

The meeting was closed at 8:30 a.m.